Stifel initiated coverage of TransMedics (TMDX) with a Hold rating and $115 price target The firm would characterize results of its survey of 19 U.S. transplant surgeons survey as “mixed,” reporting surgeon feedback suggests TransMedics’ OCS portable organ perfusion, optimization, and monitoring system may face market share pressure, driven by competition. When factoring in the mixed survey findings, the firm believe risk-reward is balanced at current levels against its “confidence in meaningful upside potential to estimates,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group: Undervalued Leader in Organ Transplantation with Strong Growth Potential
- Strategic Growth Potential and Competitive Edge: Buy Rating for TransMedics Group
- TransMedics Group’s OCS Lung: A Game-Changer in Organ Care with Promising Clinical Advancements
- TransMedics Group: Strong Performance and Strategic Initiatives Drive Buy Rating
- TransMedics Group’s Strategic Advancements and FDA Approval Drive Buy Rating